Project Grant K99CA304466
Award Date
7/9/25
Completion Date
6/30/27
Dollars Obligated
$131K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
This Project Grant award of $1,396,152.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to examine the role of the protein BNIP3 and mitophagy (selective degradation of mitochondria) in muscle atrophy during cancer cachexia associated with pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse models of PDAC to investigate how BNIP3 promotes atrophy of muscle fibers by reducing mitochondrial mass, and how reconstitution...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, supports research to investigate the role of adipose tissue (fat) in facilitating tumor growth and cancer cachexia (wasting syndrome) in lung cancer. The $129,624 award to the University of Vermont & State Agricultural College aims to employ pharmacological interventions, a novel mouse model, and in vitro studies to understand how fat substrates, both endogenous and...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $432,889 to The Johns Hopkins University to conduct research aimed at advancing cancer screening, diagnostic technologies, and early detection methodologies. The project, titled "Molecular Imaging and Metabolotheranostics of PDAC-Induced Cachexia", will focus on reversing cachexia (severe muscle wasting) induced by pancreatic ductal adenocarcinoma...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $727,732 to conduct research aimed at overcoming resistance to CDK4/6 inhibitor therapy for patients with dedifferentiated liposarcoma. The key objectives are to evaluate the efficacy of combining the CDK4/6 inhibitor palbociclib with the MEK inhibitor mirdametinib in a Phase Ib/II clinical trial, and to analyze the molecular...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $204,474 to The Regents of the University of Colorado to conduct research aimed at defining the relationship between cell quiescence and senescence. The project will use advanced microscopy techniques and RNA sequencing to study the molecular mechanisms that mediate the transition from a reversible quiescent state to permanent cell cycle arrest, or senescence. The research...
This $423,084 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Trustees of Indiana University, Indianapolis to investigate the role of the endocrine hormone FGF21 in mediating musculoskeletal wasting associated with metastatic colorectal cancer. The research aims to: 1) Interrogate FGF21-dependent effects on bone loss in advanced colorectal cancer, 2) Determine the mechanisms by which FGF21 triggers muscle wasting,...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $113,203 to the University of Chicago to investigate the immunomodulatory effects of a dietary compound called Sumiki's Acid (SKA) on natural killer (NK) cells for cancer immunoprevention. The research aims to determine SKA's potential as a cancer-preventive agent, elucidate its underlying molecular mechanisms, and explore medicinal chemistry and bioengineering approaches to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $219,491 to the Mayo Clinic Jacksonville to conduct research on the epigenetic regulation of T cell metabolism and immune functions by the SIRT6 protein. The research aims to understand how SIRT6 impacts the metabolic activity and effector functions of tumor-reactive T cells, with the goal of identifying ways to boost T cell metabolism and enhance cancer immunotherapies. The study will...